Portfolio ∣ Diamond Biofound

Close

CHO Pharma Inc.

Listed on TPEx Emerging Stock Board on September 27th, 2017 (TPEx : 6586)

Location
Taipei, Taiwan
Established Year
2013
Listed Year
2017
Website
https://www.chopharma.com/index.html

Diamond Biofund provided us timely support with their exceptional team and valuable experience.

- President, Chung-Yi Wu, Ph.D -

In fact, like most biotech companies around the world that have pioneered new fields in the past decade, CHO Pharma has had a difficult time in the process.

Diamond Biofund’s excellent team and its successful experience in coaching companies has always provided timely assistance at critical moments, allowing me, who was originally focused on academic research but not familiar with the industry, to quickly identify a development blueprint that would allow CHO Pharma to play in the World Cup. This is the biggest difference between Diamond Biofund and most of the biomedical venture capitalists who only contribute capital. We believe that we will soon achieve our vision of becoming a global glycogen technology leader in biotechnology pharmaceuticals through continued support from Diamond Biofund.

Introduction

CHO Pharma Co., Ltd. was established in March 2013 and holds an exclusive license for glycoscience-related patented technologies from Academia Sinica, including cancer vaccines, novel antibody drugs, glycan microarrays, and other related glycoscience patents. The company focuses on developing new drugs and disease diagnostic products.

Through its proprietary CHOptimax™ technology platform, CHO Pharma has successfully developed CHO-H01, the world’s first glyco-engineered biobetter drug. The company is now further expanding the applications of the CHOptimax™ platform in new drug development. Its research focuses include glyco-engineered biobetter drugs, antibody-drug conjugates with specific glycosylation sites, and novel vaccines.

Close

Sinew Pharma Inc.

Location
Taipei, Taiwan
Established Year
2014
Listed Year
2017
Website
https://www.sinewpharma.com/en/

Diamond Biofund is the nutrient and cultivator to the biotech startups

- Chairman and President, MD, PhD., Kai-Min Chu, Sinew Pharma -

Mr. Hu, Shih once said, " As you sow, so will you reap." This is an apt description of the biotech venture capital industry. In addition to a large amount of capital injection, biotech venture capitals devote more resources than the general industry, including upgrading technology and business strategies, enabling the biotechnology industry to thrive. Diamond Biofund is the nourisher and cultivator of new biotech ventures. From the start-up stage of Sinew Pharma all the way to the capital market, Diamond Biofund has always given Sinew the strongest support. In the future, Sinew will uphold the goal of solving unmet clinical needs and leading Sinew to the world.

Introduction

Sinew Pharma was founded in June 2014 with the goal of developing innovative drugs to address important unmet medical needs. The company is currently focused on two major disease areas: 1) Metabolic dysfunction–associated steatohepatitis (MASH) and its associated conditions, such as liver cirrhosis and liver cancer. 2) Acetaminophen-induced hepatotoxicity and severe liver injury.

Driven by the demands in these disease areas, Sinew Pharma is developing a novel drug for MASH and the world's first new acetaminophen with high liver safety. By addressing these critical health challenges, SINEW aspires to become a globally leading pharmaceutical company.

Current pipeline includes six products, two of which are dedicated to MASH treatment, three aim to address liver toxicity issues arising from the widely used painkiller acetaminophen and its combinations, and one serves as an antidote for acetaminophen overdose.

Related News

2024-12-25
SINEW PHARMA’s Pain Relief Drug Gains Recognition from Charles River Laboratories

Close

StemCyte Inc.

Location
Taipei, Taiwan / CA, US
Established Year
1997
Website
https://www.stemcyte.com/

Diamond is not just an investor, but a partner.

- TY Lee, Ph.D, CEO -

I have worked with Diamond for more thank 8 years. Diamnod isn't interested for a short investment.
They are trying to build a collbration and parntership. Diamond brings a deep understanding of markets and technology that is invaluable.
They are unique in being able to recognize the transformation potential of very early and unproven scientific project, and capital to bring those science to market.

Introduction

StemCyte is an international biopharmaceutical company dedicated to expanding the applications of cord blood storage and cell therapy. Founded in the United States in 1997, the company has established a strong presence in Taiwan and India. To date, StemCyte has built a public cord blood bank with over 36,000 units, making it one of the largest in scale globally, with unparalleled racial diversity and superior quality. It is also among the few biotechnology companies that operate both public and private cord blood banks.

Over the past 20 years, StemCyte has provided more than 2,300 cord blood units to over 350 transplant centers worldwide, supporting the treatment of various diseases. In November 2024, the company achieved a historic milestone by becoming the world’s first private enterprise to obtain FDA approval for a cord blood biologics license.

Additionally, StemCyte collaborates with leading medical teams both domestically and internationally to advance cell therapy technologies. The company is actively developing stem cell-based treatments using RegeneCyte for conditions such as long COVID and acute ischemic stroke. These therapies have demonstrated breakthrough progress in clinical trials, and StemCyte remains committed to expanding its research into multiple therapeutic applications.

Related News

Close

Tetanti AgriBiotech Inc.

Location
Taichung, Taiwan
Established Year
2018
Website
http://ttt3tops.com/index.aspx?lang=US

Diamond Biofund “honors the way of Nature and benefits all beings”

- Dr. Chiu-Chung Young, Academician of Academia Sinica & National Chair Professor President, -

Diamond Biofund aims at identifying innovative biotechnologies in the medical and agricultural realm that can truly impact the well-being of human and the environment.

Diamond Biofund has been a key and valued partner in assisting TTT’s transition from the academic to the industry by bringing the precise and appropriate personnel and resources to the company. With the same eco-friendly vision and sustainable support, TTT is confident to achieve our novel technology’s potential values in the worldwide market.

Introduction

Led by Academia Sinica Fellow, Yang, Chiu-Chung, Tetanti AgriBiotech has developed a rapid treatment technology using enzymes instead of microorganisms with thirty years of research results, and hopes to use this innovative knowledge technology in agricultural biotechnology to solve the current problems faced by the industry. Dr. Yang, Chiu-Chung holds a Ph.D. in Agronomy and Soil Science from the University of Hawaii. He is a pioneer in the field of organic fertilizers and soil microorganisms in Taiwan and was awarded the honor of Academia Sinica Fellow. The core TTT® technology uses targeted enzymes combined with equipment to convert organic waste into organic fertilizer in less than three hours. The research and development team of our founder, Academia Sinica Fellow, Yang, Chiu-Chung, has more than 8,000 strains and 2,500 species of functional bacteria as the source of target enzymes to provide customized enzyme combinations for different organic wastes of our customers. this threshold allows Tetanti to stand out as the leader in the field of organic waste management.

TTT® technology is efficient and cost effective, it greatly improves the maturization process of organic matter over 100 folds and can reduce pollution and increase product safety. The production process solves the odor, waste water, large area demand and time-consuming problems that are normally associated with traditional composting.

Tetanti was awarded “Taiwan’s 10 Coolest Technology Innovation Team” in 2019 and was interviewed by Discovery Channel in 2020, entitled “Taiwan Revealed: Agricultural Technology“. Tetanti will “Think Globally, Act Locally”, and we will stand firm in the circular economy trend. In response to the stringent environmental regulations and carbon emissions issues around the world, TTT® Technology will play an important key role in making agricultural sustainability no longer just a slogan!

Related News

Close

Iridium Medical Technology Co., Ltd.

Established Year
2012
Website
http://www.irmedtech.com/index_en.html

Introduction

Iridium Medical Technology Company (IMTC) is an innovative neuron-electronic interface company, and the first to develop a high-acuity spherical bionic retina HARP4k. HARP4k, IMTC’s contact-lens-shaped wireless retinal prosthesis for retinal blindness caused by Retinitis Pigmentosa (RP) and Age-related Macular Degeneration (AMD), is a 30µm-thick packaged wireless implant with integrated camera chip, convolutional image processor and a high-density 4,000-microelectrode array interfacing to the retinal neurons. HARP4k supports the acuity needed for recognizing faces and objects, reading big-print books (font size > 14 pt.), and navigating through life.

Iridium Medical Technology Company (IMTC) has developed a high-definition spherical bionic retina for patients who have lost their vision due to retinal diseases. This bionic retina has been productized and entered human clinical trials. By leveraging Taiwan’s strengths in electronics and medical technology, IMTC aims to create a world-class Class III implantable medical device, positioning Taiwan’s high-end medical technology to compete in the global market.

Close

EyeYon Medical Ltd.

Location
Israel
Website
https://eye-yon.com/

Diamond BioFund is a true example of “smart- money”

- Nahum Ferera/ CEO & Co Founder -

Diamond BioFund is a true example of “smart- money”. I am very honored to partner with a VC that understand the life-science industry, the changing environment and the multicultural differences. Diamond Biofund is also long lasting partner that was interested in seeing the company growing and succeeding to bring a true value to humankind.

Introduction

EyeYon Medical is an Israel-based medical device startup that develops innovative medical devices for the treatment of the cornea. EyeYon Medical has developed two therapeutic materials: Hyper-CL and EndoArt. Hyper-CL (High Permeability Contact Lens) is an effective non-surgical treatment for corneal edema. It is made of highly permeable contact lenses. They are disposable contact lenses and need to be replaced every two weeks. The product’s efficacy has been proven through clinical studies, is CE marked and FDA approved, and has been approved for sale in the European and US markets. EndoArt is an artificial retina replacement solution developed by EyeYon Medical that replaces the damaged endothelial layer of the eye with an artificial endothelial layer. The procedure is minimally invasive and seamless, requiring only a very small incision to insert the artificial layer. The product has already obtained the EU CE mark and received FDA approval for human clinical trials.

Related News

Close

Kendall Capital Partners

Location
Boston, US
Established Year
2021
Website
https://www.kcpventures.com/

Introduction

Kendall Capital Partners focuses on early-stage investments in the field of biotechnology and medical care. It is a Boston-based venture capital fund composed of an investment team with business incubation experience.

Close

Bilayer Therapeutics

Location
Boston, US
Established Year
2020
Website
https://bilayer-therapeutics.com

Introduction

Bilayer Therapeutics is a development-stage company co-founded in 2020 by a team of world-renowned drug development and delivery experts and gastroenterologists to stimulate the body’s innate mechanisms for regulating constipation and diarrhea. With a naturally occurring bile acid (chenodeoxycholate or CDC) delivered via proprietary bilayer tablet technology, the company is developing innovative treatments for Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation and other conditions of the colon.

CDC activates both established mechanisms of action for treating constipation: fluid flow and motility in the colon. By using CDC, Bilayer Therapeutics aims to offer more effective treatments for chronic constipation that will cause fewer side effects for patients.

Close

ImmunAdd Inc.

Location
Taipei, Taiwan
Established Year
2022
Website
http://www.immunadd.com/

Introduction

Founded in 2022, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation. ImmunAdd develops next generation saponin adjuvants and uses them as the basis for new combinations of adjuvants and adjuvanted vaccines to improve the efficacy and durability of vaccines.

Close

Rejuvenate Bio Inc.

Location
San Diego, USA
Established Year
2017
Website
https://rejuvenatebio.com/

Introduction

Rejuvenate Bio is a gene therapy company focused on treating chronic diseases based upon its breakthrough technology developed at the Wyss Institute of Harvard University. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to patients suffering from chronic conditions. The company is developing a pipeline of therapies with applications in cardiac and metabolic diseases.

Related News

Close

Syncell (Taiwan) Inc

Location
Taipei, Taiwan
Established Year
2020
Website
https://syncell.com/

Introduction

SYNCELL was officially spun off from Academia Sinica in 2020 and continues to productize and commercialize the Microscoop technology platform. SYNCELL’s Microscoop spatial proteomics technology can turn a microscope into a “Microscoop” - the world’s first in-cell “pickable” microscope that applies an AI algorithm to selectively identify proteins and nucleic acids from a specified subcellular location.

Related News